3-Bromo-4,5-dihydroxybenzaldehyde Isolated from Polysiphonia morrowii Suppresses TNF-α/IFN-γ-Stimulated Inflammation and Deterioration of Skin Barrier in HaCaT Keratinocytes

Mar Drugs. 2022 Aug 31;20(9):563. doi: 10.3390/md20090563.

Abstract

Polysiphonia morrowii is a well-known red alga that has promising pharmacological characteristics. The current study evaluates the protective effect of 3-bromo-4,5-dihydroxybenzaldehyde (BDB) isolated from P. morrowii on tumor necrosis factor (TNF)-α/interferon (IFN)-γ-stimulated inflammation and skin barrier deterioration in HaCaT keratinocytes. The anti-inflammatory effect of BDB in TNF-α/IFN-γ-stimulated HaCaT keratinocytes is evaluated by investigating nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, inflammatory cytokines, and chemokines. Further, the interaction between BDB and the skin barrier functions in stimulated HaCaT keratinocytes is investigated. The findings of the study reveal that BDB dose-dependently increases cell viability while decreasing intracellular reactive oxygen species (ROS) production. BDB downregulates the expression of inflammatory cytokines, interleukin (IL)-6, -8, -13, IFN-γ, TNF-α, and chemokines, Eotaxin, macrophage-derived chemokine (MDC), regulated on activation, normal T cells expressed and secreted (RANTES), and thymus and activation-regulated chemokine (TARC) by modulating the MAPK and NF-κB signaling pathways in TNF-α/IFN-γ-stimulated HaCaT keratinocytes. Furthermore, BDB increases the production of skin hydration proteins and tight junction proteins in stimulated HaCaT keratinocytes by preserving skin moisturization and tight junction stability. These findings imply that BDB exhibits a protective ability against inflammation and deterioration of skin barrier via suppressing the expression of inflammatory signaling in TNF-α/IFN-γ-stimulated HaCaT keratinocytes.

Keywords: 3-bromo-4,5-dihydroxybenzaldehyde; HaCaT keratinocyte; Polysiphonia morrowii; anti-inflammation; skin barrier.

MeSH terms

  • Anti-Inflammatory Agents / metabolism
  • Anti-Inflammatory Agents / pharmacology
  • Benzaldehydes* / pharmacology
  • Chemokine CCL17 / metabolism
  • Chemokine CCL22 / metabolism
  • Chemokine CCL5 / metabolism
  • Chemokines / metabolism
  • Cytokines / metabolism
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Interferon-gamma / metabolism
  • Interleukins / metabolism
  • Keratinocytes* / drug effects
  • Mitogen-Activated Protein Kinases / metabolism
  • NF-kappa B / metabolism
  • Reactive Oxygen Species / metabolism
  • Rhodophyta* / chemistry
  • STAT1 Transcription Factor / metabolism
  • Tight Junction Proteins / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • 3-bromo-4,5-dihydroxybenzaldehyde
  • Anti-Inflammatory Agents
  • Benzaldehydes
  • Chemokine CCL17
  • Chemokine CCL22
  • Chemokine CCL5
  • Chemokines
  • Cytokines
  • Interleukins
  • NF-kappa B
  • Reactive Oxygen Species
  • STAT1 Transcription Factor
  • Tight Junction Proteins
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma
  • Mitogen-Activated Protein Kinases